Matched antibody pairs refer to sets of antibodies which are known to be capable of detecting different epitopes on the same protein antigen, so they can be used together for the capture and detection of a single antigen in a sandwich ELISA or related immunoassay.
“We can provide the most suitable matched pairs for life scientists’ immunoassay research projects. Meanwhile, they can also purchase the antibodies separately. Of note, if they do not find a suitable antibody pairs at Creative Diagnostics, we can also offer custom ELISA matched Pair Development service specially for researchers!” said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
Features of matched pairs at Creative Diagnostics:
Ideal for antibody sandwich ELISA or related immunoassay
Consist of two monoclonals, two polyclonals, or a combination of both
Antibodies can be ordered in bulk quantity
“Creative Diagnostics is always working to provide our customers with the best possible products and services. One way of doing this is to listen to the wants and needs of our customers and deliver on them. That’s why we provide such products like matched pairs to our existing and new customers.” said Dr. Randy S. Vaughn, senior researcher at Creative Diagnostics.
A common problem when using 2D-bar coded tube racks straight from the freezer is "fogging" of the scanner or reader glass as condensation forms on the surface. The Ziath range of single tube scanners, compact rack readers and large multi-rack readers are all capable of reading 2D-barcoded tubes straight from the freezer.
Using an analysis tool developed by Ripeta, Digital Science has launched a report focusing on falsifiability and reproducibility in scientific research. The report addresses three areas including appropriate documentation and sharing of research data, clear analysis and processes, and the sharing of code.
IRBM has announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center, focusing on the development of therapeutic monoclonal antibodies against a novel immune checkpoint target.